PAR-1 contributes to the innate immune response during viral infection

Journal of Clinical Investigation

Volumn 123, Issue 3, 2013, Pages 1310-1322

  Antoniak, Silvio ^a   Owens III, A Phillip ^a   Baunacke, Martin ^a   Williams, Julie C ^a   Lee, Rebecca D ^a   Weithäuser, Alice ^b   Sheridan, Patricia A ^c   Malz, Ronny ^b   Luyendyk, James P ^d   Esserman, Denise A ^a,e   Trejo, Jo Ann ^f   Kirchhofer, Daniel ^g   Blaxall, Burns C ^h   Pawlinski, Rafal ^a   Beck, Melinda A ^c   Rauch, Ursula ^b   Mackman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c University of North Carolina   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e IL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GENENTECH INC   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEINASE ACTIVATED RECEPTOR 1; SINGLE STRANDED RNA; THROMBIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3 INDUCED MYOCARDITIS; COXSACKIE VIRUS INFECTION; FEMALE; FIBROBLAST; HEART INJURY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INFLUENZA A (H1N1); INNATE IMMUNITY; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS LOAD; VIRUS MYOCARDITIS;

ANIMALS; CHEMOKINE CXCL10; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; FIBRIN; HEK293 CELLS; HELA CELLS; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS; INTERFERON-BETA; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDITIS; MYOCARDIUM; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTOR, PAR-1; STAT1 TRANSCRIPTION FACTOR; THROMBIN; THROMBOPLASTIN; TOLL-LIKE RECEPTOR 3; TROPONIN I;

EID: 84874630375     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66125     Document Type: Article

References (94)

1. Loof TG, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood. 2011;118(9):2589-2598.
2. Sun H. The interaction between pathogens and the host coagulation system. Physiology (Bethesda). 2006;21:281-288. (Pubitemid 44156860)
3. Sun H, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science. 2004;305(5688):1283-1286. (Pubitemid 39129231)
4. Iwanaga S, Kawabata S. Evolution and phylogeny of defense molecules associated with innate immunity in horseshoe crab. Front Biosci. 1998;3:D973-D984.
5. Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost. 2007;5(suppl 1):24-31. (Pubitemid 46958813)
6. Hoffmann JA. Innate immunity of insects. Curr Opin Immunol. 1995;7(1):4-10.
7. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693. (Pubitemid 47207163)
8. Coughlin SR. Thrombin signalling and proteaseactivated receptors. Nature. 2000;407(6801):258-264.
9. Antoniak S, Pawlinski R, Mackman N. Proteaseactivated receptors and myocardial infarction. IUBMB Life. 2011;63(6):383-389.
10. Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol. 2010;160(2):191-203.
11. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost. 1983;49(1):5-7. (Pubitemid 13144355)
12. Key NS, et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A. 1990;87(18):7095-7099.
13. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188(11):1618-1629. (Pubitemid 38010671)
14. Antoniak S, et al. Viral myocarditis and coagulopathy: increased tissue factor expression and plasma thrombogenicity. J Mol Cell Cardiol. 2008;45(1):118-126.
15. Funderburg NT, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115(2):161-167.
16. Huerta-Zepeda A, et al. Crosstalk between coagulation and inflammation during Dengue virus infection. Thromb Haemost. 2008;99(5):936-943. (Pubitemid 351705312)
17. Shibamiya A, et al. A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. Blood. 2009;113(3):714-722.
18. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24(6):1015-1022. (Pubitemid 38737825)
19. Drake TA, Cheng J, Chang A, Taylor FB. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol. 1993;142(5):1458-1470. (Pubitemid 24058133)
20. Morrissey JH, Drake TA. Procoagulant response of the endothelium and monocytes. In: Schlag C, RedI H, eds. Pathophysiology of Shock, Sepsis and Organ Failure. New York, New York, USA: Springer-Verlag Berlin; 1993:564-574.
21. Crossman DC, Carr DP, Tuddenham EG, Pearson JD, McVey JH. The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem. 1990; 265(17):9782-9787.
22. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol. 1989;9(6):2752-2755. (Pubitemid 19148149)
23. Brand K, Fowler BJ, Edgington TS, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol. 1991;11(9):4732-4738. (Pubitemid 21895871)
24. Taylor FB, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991;33:127-134.
25. Ruf W. Emerging roles of tissue factor in viral hemorrhagic fever. Trends Immunol. 2004;25(9):461-464. (Pubitemid 39490251)
26. Levi M, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994;93(1):114-120. (Pubitemid 24030827)
27. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost. 2011;1:182-188.
28. Popovic M, Paskas S, Zivkovic M, Burysek L, Laumonnier Y. Human cytomegalovirus increases HUVEC sensitivity to thrombin and modulates expression of thrombin receptors. J Thromb Thrombolysis. 2010;30(2):164-171.
29. Sutherland MR, Friedman HM, Pryzdial EL. Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. J Thromb Haemost. 2007;5(5):1055-1061. (Pubitemid 46691737)
30. Sutherland MR, Ruf W, Pryzdial EL. Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection. Blood. 2012;119(15):3638-3645.
31. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost. 2001;86(1):298-307. (Pubitemid 32663960)
32. Cooper DM, Pechkovsky DV, Hackett TL, Knight DA, Granville DJ. Granzyme K activates proteaseactivated receptor-1. PLoS One. 2011;6(6):e21484.
33. Sabri A, et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000;86(10):1054-1061. (Pubitemid 30367864)
34. Sabri A, Short J, Guo J, Steinberg SF. Proteaseactivated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res. 2002;91(6):532-539.
35. Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol. 2005;67(1):2-11. (Pubitemid 40069960)
36. Pawlinski R, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007;116(20):2298-2306. (Pubitemid 350100336)
37. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007;102(4):350-358. (Pubitemid 46909714)
38. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. (Pubitemid 34293424)
39. Seya T, Matsumoto M, Ebihara T, Oshiumi H. Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing. Immunol Rev. 2009;227(1):44-53.
40. Bunting RA, et al. Novel antagonist antibody to TLR3 blocks poly(I:C)-induced inflammation in vivo and in vitro. Cell Immunol. 2011;poly(1):9-16.
41. Gorbea C, et al. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J Biol Chem. 2010;285(30):23208-23223.
42. Bonjardim CA, Ferreira PC, Kroon EG. Interferons: signaling, antiviral and viral evasion. Immunol Lett. 2009;122(1):1-11.
43. Fensterl V, Sen GC. Interferons and viral infections. Biofactors. 2009;35(1):14-20.
44. Hengel H, Koszinowski UH, Conzelmann KK. Viruses know it all: new insights into IFN networks. Trends Immunol. 2005;26(7):396-401. (Pubitemid 40835846)
45. Johnsen IB, Nguyen TT, Bergstrom B, Lien E, Anthonsen MW. Toll-like receptor 3-elicited MAPK activation induces stabilization of interferon-beta mRNA. Cytokine. 2012;57(3):337-346.
46. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis. 2010;52(4):274-288.
47. Negishi H, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A. 2008;105(51):20446-20451.
48. Riad A, et al. TRIF is a critical survival factor in viral cardiomyopathy. J Immunol. 2011;186(4):2561-2570.
49. Abston ED, et al. Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease. Clin Dev Immunol. 2012;2012:129486.
50. Wessely R, Klingel K, Knowlton KU, Kandolf R. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation. 2001;103(5):756-761. (Pubitemid 32144207)
51. Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation. 2004;110(23):3540-3543. (Pubitemid 39612568)
52. Kuhl U, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107(22):2793-2798. (Pubitemid 36705988)
53. Wang YX, et al. Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol Heart Circ Physiol. 2007;293(1):H69-H76.
54. Le Goffic R, et al. Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIGI-dependent antiviral responses in human lung epithelial cells. J Immunol. 2007;178(6):3368-3372. (Pubitemid 46417600)
55. Stewart MJ, Smoak K, Blum MA, Sherry B. Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response. J Virol. 2005;79(5):2979-2987. (Pubitemid 40270577)
56. Yuan J, et al. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res. 2009;104(5):628-638.
57. Weinzierl AO, et al. Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4-/CD8+ dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis. J Virol. 2008;82(16):8149-8160.
58. Moretti S, et al. The contribution of PARs to inflammation and immunity to fungi. Mucosal Immunol. 2008;1(2):156-168.
59. Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol. 2008;83(6):1309-1322. (Pubitemid 351960309)
60. Shpacovitch V, Feld M, Bunnett NW, Steinhoff M. Protease-activated receptors: novel PARtners in innate immunity. Trends Immunol. 2007;28(12):541-550.
61. Rallabhandi P, et al. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J Biol Chem. 2008;283(36):24314-24325.
62. Nhu QM, Shirey KA, Pennini ME, Stiltz J, Vogel SN. Proteinase-activated receptor 2 activation promotes an anti-inflammatory and alternatively activated phenotype in LPS-stimulated murine macrophages. Innate Immun. 2012;18(2):193-203.
63. Nhu QM, et al. Novel signaling interactions between proteinase-activated receptor 2 and Tolllike receptors in vitro and in vivo. Mucosal Immunol. 2010;3(1):29-39.
64. Khoufache K, et al. Protective role for proteaseactivated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J Immunol. 2009;182(12):7795-7802.
65. Szalay G, et al. Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes. Am J Pathol. 2006;168(5):1542-1552.
66. Zeng X, Moore TA, Newstead MW, Deng JC, Lukacs NW, Standiford TJ. IP-10 mediates selective mononuclear cell accumulation and activation in response to intrapulmonary transgenic expression and during adenovirus-induced pulmonary inflammation. J Interferon Cytokine Res. 2005;25(2):103-112. (Pubitemid 40250352)
67. Kirchhofer D, Moran P, Bullens S, Peale F, Bunting S. A monoclonal antibody that inhibits mouse tissue factor function. J Thromb Haemost. 2005;3(5):1098-1099. (Pubitemid 41632848)
68. Pisegna S, Pirozzi G, Piccoli M, Frati L, Santoni A, Palmieri G. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood. 2004;104(13):4157-4164. (Pubitemid 39620169)
69. Antoniak S, et al. Regulation of cardiomyocyte fulllength tissue factor expression and microparticle release under inflammatory conditions in vitro. J Thromb Haemost. 2009;7(5):871-878.
70. Antao-Menezes A, Turpin EA, Bost PC, Ryman-Rasmussen JP, Bonner JC. STAT-1 signaling in human lung fibroblasts is induced by vanadium pentoxide through an IFN-beta autocrine loop. J Immunol. 2008;180(6):4200-4207.
71. Jaffre F, Friedman AE, Hu Z, Mackman N, Blaxall BC. Beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation. 2012;125(24):2993-3003.
72. Schouten M, et al. Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study. Crit Care. 2010;14(2):R65.
73. Lan RS, Stewart GA, Goldie RG, Henry PJ. Altered expression and in vivo lung function of proteaseactivated receptors during influenza A virus infection in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L388-L398. (Pubitemid 38129521)
74. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One. 2009;4(1):e4127.
75. Godeny EK, Gauntt CJ. Murine natural killer cells limit coxsackievirus B3 replication. J Immunol. 1987;139(3):913-918. (Pubitemid 17107097)
76. Hardarson HS, et al. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am J Physiol Heart Circ Physiol. 2007;292(1):H251-H258. (Pubitemid 46105186)
77. Chen D, et al. Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med. 2008;205(8):1739-1746.
78. Naldini A, Carney DH. Thrombin modulation of natural killer activity in human peripheral lymphocytes. Cell Immunol. 1996;172(1):35-42. (Pubitemid 26295660)
79. Palumbo JS, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178-185. (Pubitemid 40053080)
80. Marchant D, McManus BM. Matrix metalloproteinases in the pathogenesis of viral heart disease. Trends Cardiovasc Med. 2009;19(1):21-26.
81. Cheung C, et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation. 2008;117(12):1574-1582. (Pubitemid 351440645)
82. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
83. Morrow DA, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-1413.
84. Tricoci P, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20-33.
85. Darrow AL, et al. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost. 1996;76(6):860-866. (Pubitemid 27013619)
86. Kandolf R, Hofschneider PH. Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc Natl Acad Sci U S A. 1985;82(14):4818-4822. (Pubitemid 16242981)
87. Smith AG, Sheridan PA, Harp JB, Beck MA. Dietinduced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr. 2007;137(5):1236-1243. (Pubitemid 46701917)
88. Antoniak S, et al. Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2010;30(11):2136-2142.
89. Williams JC, Lee RD, Doerschuk CM, Mackman N. Effect of PAR-2 deficiency in mice on KC expression after intratracheal LPS administration. J Signal Transduct. 2011;2011:415195.
90. Owens AP 3rd, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012;122(2):558-568.
91. Boltzen U, et al. Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-alpha-induced apoptosis. J Mol Cell Cardiol. 2012;52(5):1056-1065.
92. Wang Y, et al. Inhibition of clathrin/dynamindependent internalization interferes with LPSmediated TRAM-TRIF-dependent signaling pathway. Cell Immunol. 2012;274(1-2):121-129.
93. Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem. 2009;284(21):14136-14146.
94. Khoufache K, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013;123(1):206-214.